Get the Stockscreener App
2.65
0.38%
-0.01
After Hours:
2.65
Ac Immune Sa Stock (ACIU) Latest News
AC Immune: Leader In Dementia Therapies, A Space Littered With Failures (ACIU) - Seeking Alpha
Contrasting Silence Therapeutics (NASDAQ:SLN) & AC Immune (NASDAQ:ACIU) - Defense World
Alzheimer's Disease Clinical Trial Pipeline | 110+ Companies Pioneering Breakthroughs in Treatment | - EIN News
AltPep Corporation Appoints Alan Colowick, M.D., M.P.H. To Its Board - citybiz
AltPep Corporation Appoints Alan Colowick, M.D., M.P.H. to Board of Directors - Business Wire
Leerink Partnrs Predicts Increased Earnings for AC Immune - MarketBeat
3 US Penny Stocks With Market Caps Over $100M To Consider - Simply Wall St
Leerink Partnrs Increases Earnings Estimates for AC Immune - Defense World
New Strong Buy Stocks for January 31st - Yahoo Finance
Updates in Therapeutic Development: Clinical Trial Readouts to Watch in the First Half of 2025 - Neurology live
Five promising small-cap pharmaceutical companies taking on Alzheimer’s - Kursiv Media
AC Immune (NASDAQ:ACIU) & Assembly Biosciences (NASDAQ:ASMB) Head-To-Head Review - Defense World
Down Syndrome Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Roche, Aelis Farma, AC Immune SA, Eisai Inc., Forest Lab, Eisai Co. - The Globe and Mail
Down Syndrome Pipeline 2024: Clinical Trials Assessment, FDA - openPR
AC Immune (NASDAQ:ACIU) Shares Cross Below Fifty Day Moving AverageTime to Sell? - MarketBeat
Micron Technology (MU-Q) QuotePress Release - The Globe and Mail
Mild Cognitive Impairment Market is Predicted to Advance at a CAGR of 11.6% by 2034 | DelveInsight - The Malaysian Reserve
AC Immune (NASDAQ:ACIU) Shares Down 4.4%Here's What Happened - MarketBeat
US Penny Stocks Spotlight: AC Immune And Two Others To Consider - Simply Wall St
High Growth Tech Stocks in the United States - Simply Wall St
Japan deals big, wins approvals, mulls CGT; Korea, Australia, too - BioWorld Online
AC Immune SA's (NASDAQ:ACIU) last week's 11% decline must have disappointed retail investors who have a significant stake - Simply Wall St
AC Immune Announces Key Executive Promotions to Strengthen R&D Leadership - TipRanks
AC Immune (NASDAQ:ACIU) Stock Crosses Below 200-Day Moving AverageHere's What Happened - MarketBeat
AC Immune announces interim safety, tolerability data from ABATE Phase 1b/2 - Yahoo Finance
AC Immune's ABATE Trial Shows Positive Safety Data in Down Syndrome - Investing.com Canada
AC Immune Announces Promising Safety Data for Down Syndrome Therapy - TipRanks
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome - GlobeNewswire
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome - GlobeNewswire Inc.
Adv Micro Devices (AMD-Q) QuotePress Release - The Globe and Mail
Acadia signs agreement with Saniona to commercialise SAN711 - Pharmaceutical Technology
AC Immune Q3 2024: Strong Progress and Financial Turnaround - TipRanks
HC Wainwright Reaffirms “Buy” Rating for AC Immune (NASDAQ:ACIU) - Defense World
AC Immune’s stock jumps after Parkinson’s therapy shows signs of benefit - Clinical Trials Arena
AC Immune (NASDAQ:ACIU) Given "Buy" Rating at HC Wainwright - MarketBeat
AC Immune reports interim results from Phase 2 trial of ACI-7104.056 - Yahoo Finance
AC Immune (ACIU) Sees Stock Boost Following Positive Trial Data - Stocks Telegraph
Short Interest in AC Immune SA (NASDAQ:ACIU) Increases By 23.5% - MarketBeat
AC Immune SA (NASDAQ:ACIU) Short Interest Up 23.5% in October - Defense World
AC Immune stock jumps 20% on data for Parkinson's disease drug (NASDAQ:ACIU) - Seeking Alpha
S&P 500 Moves Lower; US Crude Oil Inventories Increase - Benzinga
AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients - Benzinga
AC Immune Phase II ACI-7104.056 success in Parkinson’s - The Pharma Letter
AC Immune's Parkinson's vaccine shows promise in early trial - Investing.com India
AC immune announces positive trial results for early Parkinson’s treatment - PharmaTimes
AC Immune’s Promising Trial Results for Parkinson’s Therapy - TipRanks
Immunotherapy in Early Parkinson’s Disease Posts Positive Interim Results from Phase 2 Study - Precision Vaccinations
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):